Company / EPS (Diluted)
SANGAMO THERAPEUTICS, INC EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.49
FY2025
5-year range
-$1.48 / -$0.49
FY2021-FY2025
Trend
+66.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) returned to growth in FY2025 after 4 years of decline, reaching $-0.49.
Based on SEC 10-K filings.
-0.49 in FY2025.
Improved from $-1.23 to $-0.49 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 66.9% year-over-year.
- Peak eps (diluted) was recorded in FY2016.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -28.87 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.49 | +66.9% |
| FY2024 | -$1.48 | -20.3% |
| FY2023 | -$1.23 | -36.7% |
| FY2022 | -$0.90 | -5.9% |
| FY2021 | -$0.85 | -21.4% |
| FY2020 | -$0.70 | +0.0% |
| FY2019 | -$0.70 | +31.4% |
| FY2018 | -$1.02 | -75.9% |
| FY2017 | -$0.58 | -48.7% |
| FY2016 | -$0.39 | +18.7% |